$PKTX
ProtoKinetix, Inc.

2023 Q2 Form 10-Q Financial Statement

#000107997323000958 Filed on July 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $72.03K $338.5K
YoY Change -78.72% -11.42%
% of Gross Profit
Research & Development $31.98K $102.9K
YoY Change -68.93% -4.89%
% of Gross Profit
Depreciation & Amortization $11.57K $750.00
YoY Change 1442.67% 0.0%
% of Gross Profit
Operating Expenses $115.6K $442.2K
YoY Change -73.86% 9.52%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$115.6K -$442.2K
YoY Change -73.86% -17.07%
Income Tax
% Of Pretax Income
Net Earnings -$115.6K $442.2K
YoY Change -126.14% -209.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 $0.00
Diluted Earnings Per Share $0.00 -$1.519K
COMMON SHARES
Basic Shares Outstanding 327.9M shares 291.0M shares
Diluted Shares Outstanding 335.6M shares 291.0M shares

Balance Sheet

Concept 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.66K $18.83K
YoY Change -0.9% -77.74%
Cash & Equivalents $18.66K $18.83K
Short-Term Investments
Other Short-Term Assets $1.050K $1.050K
YoY Change 0.0% 0.0%
Inventory
Prepaid Expenses $1.050K $1.050K
Receivables
Other Receivables
Total Short-Term Assets $19.71K $19.88K
YoY Change -0.86% -76.79%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $447.3K $393.2K
YoY Change 13.76% 22.93%
TOTAL ASSETS
Total Short-Term Assets $19.71K $19.88K
Total Long-Term Assets $447.3K $393.2K
Total Assets $467.0K $413.0K
YoY Change 13.06% 1.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.26K $36.78K
YoY Change -63.95%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.26K $36.78K
YoY Change -63.95% 635.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $13.26K $36.78K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $13.26K $36.78K
YoY Change -63.95% 635.6%
SHAREHOLDERS EQUITY
Retained Earnings -$47.67M -$46.49M
YoY Change 2.53%
Common Stock $1.795K $1.641K
YoY Change 9.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $453.7K $376.3K
YoY Change
Total Liabilities & Shareholders Equity $467.0K $413.0K
YoY Change 13.06% 1.86%

Cashflow Statement

Concept 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$115.6K $442.2K
YoY Change -126.14% -209.52%
Depreciation, Depletion And Amortization $11.57K $750.00
YoY Change 1442.67% 0.0%
Cash From Operating Activities -$143.8K -$163.6K
YoY Change -12.15% -52.46%
INVESTING ACTIVITIES
Capital Expenditures $19.53K -$26.41K
YoY Change -173.95% 128.26%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$19.53K -$26.41K
YoY Change -26.05% 128.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 175.0K 150.0K
YoY Change 16.67% -21.05%
NET CHANGE
Cash From Operating Activities -143.8K -163.6K
Cash From Investing Activities -19.53K -26.41K
Cash From Financing Activities 175.0K 150.0K
Net Change In Cash 11.72K -40.05K
YoY Change -129.26% -75.84%
FREE CASH FLOW
Cash From Operating Activities -$143.8K -$163.6K
Capital Expenditures $19.53K -$26.41K
Free Cash Flow -$163.3K -$137.2K
YoY Change 18.98% -58.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001128189
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
PKTX Fair Value Of Compensatory Options Granted
FairValueOfCompensatoryOptionsGranted
usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-32917
dei Entity Registrant Name
EntityRegistrantName
PROTOKINETIX, INCORPORATED
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3355026
dei Entity Address Address Line1
EntityAddressAddressLine1
109 W Main St.
dei Entity Address City Or Town
EntityAddressCityOrTown
Dalton
dei Entity Address State Or Province
EntityAddressStateOrProvince
OH
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
44618
dei City Area Code
CityAreaCode
740
dei Local Phone Number
LocalPhoneNumber
434-5041
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
335630151 shares
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18655 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
25550 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1050 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1050 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
19705 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
26600 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
447275 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
436270 usd
CY2023Q2 us-gaap Assets
Assets
466980 usd
CY2022Q4 us-gaap Assets
Assets
462870 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
13255 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
41530 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13255 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
41530 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000053
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000053
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
335630151 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
335630151 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
322880151 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
322880151 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1795 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1726 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48123024 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47868093 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47671094 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47448479 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
453725 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
421340 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
466980 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462870 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11563 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
750 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
22266 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35715 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56487 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
68477 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
114538 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
36318 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
40139 usd
us-gaap Professional Fees
ProfessionalFees
77211 usd
us-gaap Professional Fees
ProfessionalFees
87892 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31981 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
102924 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54661 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
265974 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
241853 usd
us-gaap Share Based Compensation
ShareBasedCompensation
483706 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
115577 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
442153 usd
us-gaap Operating Expenses
OperatingExpenses
222615 usd
us-gaap Operating Expenses
OperatingExpenses
953610 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-115577 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-442153 usd
us-gaap Net Income Loss
NetIncomeLoss
-222615 usd
us-gaap Net Income Loss
NetIncomeLoss
-953610 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
335630151 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
335630151 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
290989603 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
290989603 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
328025179 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
328025179 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
282228660 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
282228660 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
421340 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
255000 usd
us-gaap Profit Loss
ProfitLoss
-222615 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
453725 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
394302 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
175000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-115577 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
453725 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
352966 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
493200 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
483706 usd
us-gaap Profit Loss
ProfitLoss
-953610 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
376262 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
426562 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
150000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
241853 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-442153 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
376262 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-222615 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-953610 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
22266 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
1500 usd
PKTX Fair Value Of Compensatory Options Granted
FairValueOfCompensatoryOptionsGranted
483706 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-24945 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-28275 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-56488 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-228624 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-499947 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
33271 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
31991 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33271 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31991 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
255000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
493200 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
255000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
493200 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6895 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-38738 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25550 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57568 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18655 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18830 usd
CY2015 PKTX Payment To Acquire Intangible Assets
PaymentToAcquireIntangibleAssets
30000 usd
CY2015Q4 PKTX Additional Patent Applications
AdditionalPatentApplications
10000 usd
CY2015 PKTX Warrant Issued
WarrantIssued
6000000 shares
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
25000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zvBYD0J9EYNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_86A_zxZ8knuV0Mq5">Use of Estimates</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to valuation of equity related instruments issued, deferred income taxes, and the useful life and impairment of intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2023Q2 us-gaap Deposits Assets
DepositsAssets
1050 usd
CY2022Q4 us-gaap Deposits Assets
DepositsAssets
1050 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
382171 usd
CY2022 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
132049 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
514220 usd
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
33271 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
547491 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19500 usd
CY2022 PKTX Amortization
Amortization
58450 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
77950 usd
PKTX Amortization
Amortization
22266 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
100216 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
436270 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
447275 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
22266 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500 usd
CY2015Q4 PKTX Additional Patent Applications
AdditionalPatentApplications
10000 usd
CY2015 PKTX Warrant Issued
WarrantIssued
6000000 shares
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
33271 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
94290000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
94290000 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13300000 shares
CY2023Q2 PKTX Common Stock Shares Authorizeds
CommonStockSharesAuthorizeds
500000000 shares
CY2022Q4 PKTX Common Stock Shares Authorizeds
CommonStockSharesAuthorizeds
500000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000053
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000053
CY2023Q2 us-gaap Dividends Receivable
DividendsReceivable
0 usd
CY2022Q2 us-gaap Dividends Receivable
DividendsReceivable
0 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5250000 shares
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.06
CY2022Q1 PKTX Options Expiration Date
OptionsExpirationDate
2030-03-14
CY2023Q2 PKTX Due To Related Parties Currents
DueToRelatedPartiesCurrents
0 usd
CY2022Q2 PKTX Due To Related Parties Currents
DueToRelatedPartiesCurrents
0 usd

Files In Submission

Name View Source Status
0001079973-23-000958-index-headers.html Edgar Link pending
0001079973-23-000958-index.html Edgar Link pending
0001079973-23-000958.txt Edgar Link pending
0001079973-23-000958-xbrl.zip Edgar Link pending
ex31x1.htm Edgar Link pending
ex31x2.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pktx-20230630.xsd Edgar Link pending
pktx_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pktx-20230630_def.xml Edgar Link unprocessable
pktx-20230630_lab.xml Edgar Link unprocessable
pktx-20230630_pre.xml Edgar Link unprocessable
pktx_10q_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pktx-20230630_cal.xml Edgar Link unprocessable